|Videos|March 10, 2023
A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care
Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.
Advertisement
Episodes in this series
January 2023 AbbVie Inc. Company Confidential
Advertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
ASTRO now recommends moderate hypofractionation for all risk groups and SBRT as a standard option in low- and intermediate-risk localized prostate cancer.
Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Which New Service Lines Should a Radiation Oncology Department Launch?
5